Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial

CONTEXT: Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. OBJECTIVES: We assessed the cardiovascular safety profile of abaloparatide. DESIGN: Review of heart rate (HR...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Endocrinol Metab
Hlavní autoři: Cosman, Felicia, Peterson, Linda R, Towler, Dwight A, Mitlak, Bruce, Wang, Yamei, Cummings, Steven R
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Clinical Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7500469/
https://ncbi.nlm.nih.gov/pubmed/32658264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgaa450
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky